|

Harald Ekman
David V. Goeddel, Ph.D.
Richard Klausner, M.D.
Magnus Persson, M.D., Ph.D.
Peter Svennilson

David Baltimore, Ph.D.
Michael S. Brown, M.D.
Joseph L. Goldstein, M.D.
Tom Maniatis, Ph.D.

Tim Kutzkey, Ph.D.
Gregory S. Naeve, Ph.D.
Dee Datta, Ph.D.

Grant Heidrich

|
|
Mr. Svennilson has twenty-three years of experience in
corporate finance, investment banking, and venture capital. He was the founder
and a partner of Three Crowns Capital, a leading backer of a new generation of
U.S. biotechnology companies. He helped found companies like Rosetta, PTC,
Tercica and Somalogic and over the past twelve years has helped finance and
develop biotech companies such as Tularik, Sunesis, Chemocentryx, Infinity,
AVEO, Rinat and FivePrime. He is currently a Board Director of NGM Biopharmaceuticals
and Aragon Pharmaceuticals and has served on the Board of Directors of several other biotechnology
companies including Rosetta, PTC, Somalogic and ChemoCentryx. Prior to Three
Crowns Capital he was the Associate Managing Director in charge of European
Investment Banking Origination at Nomura Securities in London. Mr. Svennilson is
currently a Trustee for The Institute for Advanced Study in Princeton, New
Jersey.
TCG Board Representation: Aragon Pharmaceuticals, NGM Biopharmaceuticals
|